Optimal control of the SIR model in the presence of transmission and treatment uncertainty

Johns Hopkins University & Medicine, Coronavirus Resource Center, 2020 [cited 2020 2020]; Available from: https://coronavirus.jhu.edu/. World Health Organization, 2020 World Health Organization, 2020 Cooper, 2020 Haleem, 2020, Effects of COVID 19 pandemic in daily life, Curr. Med. Res. Practice, 10, 78, 10.1016/j.cmrp.2020.03.011 Sette, 2020, Pre-existing immunity to SARS-CoV-2: the knowns and unknowns, Nat. Rev. Immunol. di Mauro, 2020, SARS-Cov-2 infection: Response of human immune system and possible implications for the rapid test and treatment, Int. Immunopharmacol., 84 Centers for Disease Control and Prevention, How COVID-19 Spreads [cited 2020 July 11]; Available from: https://www.cdc.gov/coronavirus/2019-ncov/prevent-getting-sick/how-covid-spreads.html. Kimball, 2020, 377 Z. Wu, J.M. McGoogan, Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases From the Chinese Center for Disease Control and Prevention. LID - DOI: 10.1001/jama.2020.2648 [doi] FAU - Wu, Zunyou (1538-3598 (Electronic)). COVID-19 Treatment Guidelines Panel, Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. N.I.o. Health. Editor, 2019. J.A.-O. Beigel, et al. Remdesivir for the Treatment of Covid-19 - Preliminary Report. LID - DOI: 10.1056/NEJMoa2007764 [doi] LID - NEJMoa2007764 (1533-4406 (Electronic)). J. Geleris, et al. Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19 (1533-4406 (Electronic)). M.A.-O. Mahévas, et al. Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data (1756-1833 (Electronic)). Wang, 2020, Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial, Lancet, 395, 1569, 10.1016/S0140-6736(20)31022-9 H. Heesterbeek, et al. Modeling infectious disease dynamics in the complex landscape of global health (1095-9203 (Electronic)). Kermack, 1937, Contributions to the mathematical theory of epidemics: IV. Analysis of experimental epidemics of the virus disease mouse ectromelia, J. Hyg., 37, 172, 10.1017/S0022172400034902 Awerbuch, 1994, Evolution of mathematical models of epidemics, Ann. New York Acad. Sci., 740, 232, 10.1111/j.1749-6632.1994.tb19873.x Nelson, 2007 Hethcote, 2000, The mathematics of infectious diseases, SIAM Rev., 42, 599, 10.1137/S0036144500371907 Allen, 2008, An introduction to stochastic epidemic models, 81 Allen, 2000, Comparison of deterministic and stochastic SIS and SIR models in discrete time, Math. Biosci., 163, 1, 10.1016/S0025-5564(99)00047-4 M. Ishikawa, Stochastic optimal control of an sir epidemic model with vaccination, in: Proceedings of the ISCIE International Symposium on Stochastic Systems Theory and its Applications. 2012. The ISCIE Symposium on Stochastic Systems Theory and Its Applications. Bolzoni, 2017, Time-optimal control strategies in SIR epidemic models, Math. Biosci., 292, 86, 10.1016/j.mbs.2017.07.011 Cox, 1989, Optimal consumption and portfolio policies when asset prices follow a diffusion process, J. Econom. Theory, 49, 33, 10.1016/0022-0531(89)90067-7 Wachter, 2002, Portfolio and consumption decisions under mean-reverting returns: An exact solution for complete markets, J. Financial Quant. Anal., 63, 10.2307/3594995 Liu, 2007, Portfolio selection in stochastic environments, Rev. Financ. Stud., 20, 1, 10.1093/rfs/hhl001 Merton, 1973, An intertemporal capital asset pricing model, Econometrica, 867, 10.2307/1913811 Markowitz, 1952, Portfolio selection*, J. Finance, 7, 77 Ingersoll, 1987 Centers for Disease Control and Prevention United States COVID-19 Cases and Deaths by State over Time. (Accessed 11 September 2020). Available from: https://data.cdc.gov/Case-Surveillance/United-States-COVID-19-Cases-and-Deaths-by-State-o/9mfq-cb36. COVID Tracking Project at the Atlantic. (Accessed 11 September 2020). Available from: https://covidtracking.com/data. Johns Hopkins University Coronavirus Resource Center. (Accessed 10 January 2020). Available from: https://coronavirus.jhu.edu/data/mortality. United States Census Bureau Census data. (Accessed 10 January 2020). Available from: https://www.census.gov/topics/population.html. Beigel, 2020, Remdesivir for the treatment of COVID-19 - Final report, New Engl. J. Med., 10.1056/NEJMoa2007764 Wang, 2020, Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial, Lancet, 395, 1569, 10.1016/S0140-6736(20)31022-9 Spinner, 2020, Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: a randomized clinical trial, JAMA., 324, 1048, 10.1001/jama.2020.16349 Goldman, 2020, Remdesivir for 5 or 10 days in patients with severe COVID-19, New Engl. J. Med., 10.1056/NEJMoa2015301 Centers for Disease Control and Prevention COVID-19 Pandemic Planning Scenarios. Updated 9/10/20. Available at: https://www.cdc.gov/coronavirus/2019-ncov/hcp/planning-scenarios.html. National Institutes of Health COVID-19 Treatment Guidelines. Updated 12/14/20. Available at: https://www.covid19treatmentguidelines.nih.gov/.